Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), has scheduled an investor presentation for October 21, 2026, at 9 a.m. EDT. The event will highlight the company's lead candidates: HLP003, in Phase 3 development for the adjunctive treatment of major depressive disorder (MDD), and HLP004, in Phase 2 for generalized anxiety disorder (GAD). The presentation will also include insights from key opinion leaders on the evolving depression and anxiety treatment landscape, followed by a Q&A session with Helus Pharma executives. A live webcast will be accessible through the company's website, with a replay available afterward.
The announcement matters because it puts a spotlight on two programs that could reshape treatment paradigms for conditions that affect millions worldwide. Major depressive disorder and generalized anxiety disorder are among the most prevalent mental health disorders, and existing therapies often leave patients with inadequate relief or intolerable side effects. Helus Pharma's NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, potentially offering durable improvements. HLP003 has already received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a status that expedites development and review for drugs that may demonstrate substantial improvement over existing therapies. That designation, combined with Phase 3 progress, positions HLP003 as a potential near-term catalyst. Meanwhile, HLP004's Phase 2 work in GAD signals a broader pipeline strategy.
For investors, the presentation is a chance to gauge the company's clinical momentum and commercial prospects. Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and operates in Canada, the United States, the United Kingdom, and Ireland. With an extensive research portfolio of investigational NSAs, the company aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. The event may also shed light on the competitive landscape and the company's positioning within it.
The news was disseminated on behalf of Helus Pharma and may include paid advertising. For more details, the full press release is available at https://ibn.fm/akaNj. Additional information about the company can be found at www.helus.com.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is part of the Dynamic Brand Portfolio at IBN. The platform provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit https://www.BioMedWire.com. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
